Literature DB >> 33380423

Kidney-disease-associated variants of Apolipoprotein L1 show gain of function in cation channel activity.

Jonathan Bruno1, John C Edwards2.   

Abstract

Variants in Apolipoprotein L1 (ApoL1) are known to be responsible for increased risk of some progressive kidney diseases among people of African ancestry. ApoL1 is an amphitropic protein that can insert into phospholipid membranes and confer anion- or cation-selective permeability to phospholipid membranes depending on pH. Whether these activities differ among the variants or whether they contribute to disease pathogenesis is unknown. We used assays of voltage-driven ion flux from phospholipid vesicles and of stable membrane association to assess differences among ApoL1 isoforms. There is a significant (approximately twofold) increase in the cation-selective ion permease activity of the two kidney-disease-associated variants compared with the reference protein. In contrast, we find no difference in the anion-selective permease activity at low pH among the isoforms. Compared with the reference sequence, the two disease-associated variants show increased stable association with phospholipid vesicles under conditions that support the cation permease activity, suggesting that the increased activity may be due to more efficient membrane association and insertion. There is no difference in membrane association among isoforms under optimal conditions for the anion permease activity. These data support a model in which enhanced cation permeability may contribute to the progressive kidney diseases associated with high-risk ApoL1 alleles.
Copyright © 2021 THE AUTHORS. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ApoL1; FSGS; apolipoprotein; cation channel; chloride channel; ion channel; kidney; phospholipid vesicle; potassium channel; protein–lipid interaction

Year:  2021        PMID: 33380423      PMCID: PMC7948812          DOI: 10.1074/jbc.RA120.013943

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  18 in total

1.  Association of trypanolytic ApoL1 variants with kidney disease in African Americans.

Authors:  Giulio Genovese; David J Friedman; Michael D Ross; Laurence Lecordier; Pierrick Uzureau; Barry I Freedman; Donald W Bowden; Carl D Langefeld; Taras K Oleksyk; Andrea L Uscinski Knob; Andrea J Bernhardy; Pamela J Hicks; George W Nelson; Benoit Vanhollebeke; Cheryl A Winkler; Jeffrey B Kopp; Etienne Pays; Martin R Pollak
Journal:  Science       Date:  2010-07-15       Impact factor: 47.728

2.  APOL1 risk variants, race, and progression of chronic kidney disease.

Authors:  Afshin Parsa; W H Linda Kao; Dawei Xie; Brad C Astor; Man Li; Chi-yuan Hsu; Harold I Feldman; Rulan S Parekh; John W Kusek; Tom H Greene; Jeffrey C Fink; Amanda H Anderson; Michael J Choi; Jackson T Wright; James P Lash; Barry I Freedman; Akinlolu Ojo; Cheryl A Winkler; Dominic S Raj; Jeffrey B Kopp; Jiang He; Nancy G Jensvold; Kaixiang Tao; Michael S Lipkowitz; Lawrence J Appel
Journal:  N Engl J Med       Date:  2013-11-09       Impact factor: 91.245

3.  ApoL1 Overexpression Drives Variant-Independent Cytotoxicity.

Authors:  John F O'Toole; William Schilling; Diana Kunze; Sethu M Madhavan; Martha Konieczkowski; Yaping Gu; Liping Luo; Zhenzhen Wu; Leslie A Bruggeman; John R Sedor
Journal:  J Am Soc Nephrol       Date:  2017-11-27       Impact factor: 10.121

4.  Preparation of liposomes of defined size distribution by extrusion through polycarbonate membranes.

Authors:  F Olson; C A Hunt; F C Szoka; W J Vail; D Papahadjopoulos
Journal:  Biochim Biophys Acta       Date:  1979-10-19

Review 5.  The function of apolipoproteins L.

Authors:  B Vanhollebeke; E Pays
Journal:  Cell Mol Life Sci       Date:  2006-09       Impact factor: 9.261

6.  APOL1 Renal-Risk Variants Induce Mitochondrial Dysfunction.

Authors:  Lijun Ma; Jeff W Chou; James A Snipes; Manish S Bharadwaj; Ann L Craddock; Dongmei Cheng; Allison Weckerle; Snezana Petrovic; Pamela J Hicks; Ashok K Hemal; Gregory A Hawkins; Lance D Miller; Anthony J A Molina; Carl D Langefeld; Mariana Murea; John S Parks; Barry I Freedman
Journal:  J Am Soc Nephrol       Date:  2016-11-07       Impact factor: 10.121

7.  Production of large unilamellar vesicles by a rapid extrusion procedure: characterization of size distribution, trapped volume and ability to maintain a membrane potential.

Authors:  M J Hope; M B Bally; G Webb; P R Cullis
Journal:  Biochim Biophys Acta       Date:  1985-01-10

8.  Membrane permeabilization by trypanosome lytic factor, a cytolytic human high density lipoprotein.

Authors:  John M Harrington; Sawyer Howell; Stephen L Hajduk
Journal:  J Biol Chem       Date:  2009-03-26       Impact factor: 5.157

9.  Apolipoprotein L1, a novel Bcl-2 homology domain 3-only lipid-binding protein, induces autophagic cell death.

Authors:  Guanghua Wan; Siqin Zhaorigetu; Zhihe Liu; Ramesh Kaini; Zeyu Jiang; Chien-an A Hu
Journal:  J Biol Chem       Date:  2008-05-26       Impact factor: 5.157

Review 10.  Apolipoprotein L1 nephropathies: 2017 in review.

Authors:  Jeffrey B Kopp; Hila Roshanravan; Koji Okamoto
Journal:  Curr Opin Nephrol Hypertens       Date:  2018-05       Impact factor: 2.894

View more
  3 in total

1.  Cation Channel Activity of Apolipoprotein L1 is Modulated by Haplotype Background.

Authors:  Rebecca L Winkler; Jonathan Bruno; Paula Buchanan; John C Edwards
Journal:  J Am Soc Nephrol       Date:  2022-07-15       Impact factor: 14.978

Review 2.  The evolving story of apolipoprotein L1 nephropathy: the end of the beginning.

Authors:  Parnaz Daneshpajouhnejad; Jeffrey B Kopp; Cheryl A Winkler; Avi Z Rosenberg
Journal:  Nat Rev Nephrol       Date:  2022-02-25       Impact factor: 42.439

3.  Structures of the ApoL1 and ApoL2 N-terminal domains reveal a non-classical four-helix bundle motif.

Authors:  Mark Ultsch; Michael J Holliday; Stefan Gerhardy; Paul Moran; Suzie J Scales; Nidhi Gupta; Francesca Oltrabella; Cecilia Chiu; Wayne Fairbrother; Charles Eigenbrot; Daniel Kirchhofer
Journal:  Commun Biol       Date:  2021-07-27
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.